KR970704675A - 치환된 벤즈아미딘, 이의 제조방법 및 약제로서의 이의 용도(Substituted benzamidines, their production and their use as medicaments) - Google Patents

치환된 벤즈아미딘, 이의 제조방법 및 약제로서의 이의 용도(Substituted benzamidines, their production and their use as medicaments) Download PDF

Info

Publication number
KR970704675A
KR970704675A KR1019970700124A KR19970700124A KR970704675A KR 970704675 A KR970704675 A KR 970704675A KR 1019970700124 A KR1019970700124 A KR 1019970700124A KR 19970700124 A KR19970700124 A KR 19970700124A KR 970704675 A KR970704675 A KR 970704675A
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
formula
group
methyl
Prior art date
Application number
KR1019970700124A
Other languages
English (en)
Other versions
KR100421580B1 (ko
Inventor
랄프 안더스케비츠
쿠르트 슈롬
에른스트-옷토 렌트
프란츠 비르케
아르민 휘크너
후베르트 호이어
크리스토퍼 미드
Original Assignee
라우딘 디터, 호프만 루돌프
베링거 인겔하임 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라우딘 디터, 호프만 루돌프, 베링거 인겔하임 카게 filed Critical 라우딘 디터, 호프만 루돌프
Publication of KR970704675A publication Critical patent/KR970704675A/ko
Application granted granted Critical
Publication of KR100421580B1 publication Critical patent/KR100421580B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

화학식(Ⅰ)의 신규한 화합물(여기서, A 및 R1내지 R4는 명세서에 정의한 바와 같다)은 통상적인 방법으로 제조할 수 있고, 예를 들면, LTB4길항제로서 치료적으로 사용할 수 있다.

Description

치환된 벤즈아미딘, 이의 제조방법 및 약제로서의 이의 용도 (Sunstituted benzamidines, their production and their use as medicaments)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 하기 화학식(Ⅰ)의 치환된 벤즈아미딘.
    상기 화학식(Ⅰ)에서, A는 하기 화학식(Ⅱ)의 그룹 또는 하기 화학식(Ⅲ)의 그룹이고, R1은 OH, CN, COR12〔여기서, R12는 C1-C6-알킬, C5-C7-사이클로알킬, 아릴, 헤테로아릴, 아르알킬 또는 헤테로아릴-(C1-C6-알킬)(여기서, 아릴 또는 헤테로아릴 그룹은 Cl, F, CF3, C1-C4-알킬, OH 또는 C1-C4-알콕시에 의해 일치환되거나 다치환될 수 있다)이다〕. COOR12(여기서, R12는 위에서 정의한 바와 같다) 또는 CHO이며, R2는 Br, Cl, F, CF3, OH, C1-C6-알킬, C5-C7-사이크로알킬, 아릴, O-아릴, CH2-아릴, CR5R6-아릴〔여기서, R5는 C5-C4-알킬, CH3,CH2OH, COOH 또는 COO(C1-C4-알킬)이고, R6은 H, C1-C4-알킬 또는 CF3이며, R5와 R6은 함께 C4-C6-알킬렌을 형성할 수 있다〕. C(CH3)2-R7〔여기서, R7은 CH2OH, COOH, COO(C1-C4-알킬), CONR10R11{여기서, R10은 H, C1-C6-알킬, 페닐, 페닐-(C1-C6-알킬), COR12(여기서, R12는 위에서 정의한 바와 같다), COOR12(여기서, R12는 위헤서 정의한 바와 같다), CHO, CONH2, CONHR12(여기서, R12는 위에서 정의한 바와 같다), SO2-(C1-C6-알킬) 또는 SO2-페닐(여기서, 페닐 그룹은 Cl, F, CF3, C1-C4-알킬, OH 및/또는 C1-C4-알콕시에 의해 일치환되거나 다치환될 수 있다)이고, R11은 H 또는 C1-C6-알킬이며, R10과 R11은 함께 C4-C5-알킬렌 그룹을 형성할 수 있다} 또는 CH2NR10R11(여기서, R10및 R11은 위에서 정의한 바와 같다)이다〕이고 A가 하기 화학식(Ⅲ)의 그룹이거나, X2가 하기 화학식(Ⅳ)의 그룹인 경우에는 R2는 또한 H이며, A가 하기 화학식(Ⅳ)의 그룹이다)인 경우나 A가 하기 화학식(Ⅲ)의 그룹이거나 X2가 하기 화학식(Ⅳ)의 그룹인 경우에는 R2는 또한 H이며, A가 하기 화학식(Ⅱ)의 그룹(여기서, X1은 이하 정의하는 바와 같고, X2는 NH, NCH3또는 하기 화학식(Ⅳ)의 그룹이다)인 경우에는 R2는 또한 C1-C6-알콕시이고, R3은 H, C1-C6-알킬, OH, Cl 또는 F이며, R2가 아릴, O-아릴, CH2-아릴, CR5R6-아릴(여기서, R5및 R6은 위에서 정의한 바와 같다) 또는 C(CH3)2-R7(여기서, R7은 위에서 정의한 바와 같다)인 경우나 X2가 하기 화학식(Ⅳ)의 그룹인 경우에는 R3은 또한 C1-C6-알콕시이고, R2와 R3은 함께 융합된 방향족 또는 헤테로방향족환을 형성할 수 있으며, R4는 H 또는 C1-C6-알킬이다.
    상기 화학식(Ⅱ) 및 (Ⅲ)에서, X1은 O, NH 또는 NCH3이고, X2는 O, NH, NCH3또는 하기 화학식(Ⅳ)의 그룹이며, m은 2내지 4이고, X3및X4는 각각 -X-CnH2n-(여기서, X는 0,NH 또는 NCH3이고, n은 1 또는 2이다)이며, R8및 R9는 각각H, Br, Cl, F,OH, C1-C6-알콕시이다.
    상기 화학식(Ⅳ)에서, X1은 위에서 정의한 바와 같다.
  2. 제1항에 있어서, 아릴이 페닐 또는 일치환되거나 다치환된 페닐을 나타내고 헤테로아릴이 피리딜, 피리다지닐, 피리미딜, 피라지닐, 티에닐 또는 푸릴을 나타내는 화합물.
  3. 제1항 또는 제2항에 있어서, A, m, n, X3, X4및 R1이 제1항에서 정의한 바와 같고 X1이 0이며 X2가 0 또는 화학식(Ⅳ)의 그룹(여기서, X1은 0이다)이고 R2가 Cl, F, CF3, OH, C1-C6-알킬, 아릴, 0-아릴, CH2-아릴 또는 CR5R5-아릴(여기서, R5는 C1-C3-알킬, CF3또는 CH2OH이고, R6은 H,C1-C3-알킬 또는 CF3이며, R5와 R6은 함께 C4-C5-알킬렌을 형성할 수 있다)이며 R2가 화학식(Ⅳ)의 그룹인 경우에는 R2는 또한 C1-C6-알콕시일 수 있고, R3이 H, C1-C6-알킬 또는 OH이며 R2가 CR5R6-아릴(여기서, R5및 R6은 위에서 정의한 바와 같다)인 경우에는 R3은 또한 C1-C6-알콕시이고 R4가 H이며 R8및R9가 H, F 또는 OH인 화합물.
  4. 제1항 또는 제2항에 있어서, X1이 0이고 X2가 화학식(Ⅳ)의 그룹(여기서, X1은 0이다)이며 X가 0이고 R1이 COOR12(여기서, R12는 C1-C6-알킬, 아르알킬 또는 C5-C7-사이클로알킬이다)이며 R2가 C1-C6-알킬, 아릴, 0-아릴, CH2-아릴 또는 CR5R5-아릴(여기서, R5및 R6은 C1-C3-알킬, CF3이다)이고 R3이 H, OH 또는 C1-C6-알킬 이며 R2가 CR5R5-아릴(여기서, R5와 R6은 위에서 정의한 바와 같다)인 경우엔 R3은 또한 C1-C6-알콕시이고 R8및 R9가 H인 화합물.
  5. (메톡시카보닐-이미노-{4'-〔2-(2-프로페녹시)에톡시〕비페닐-4-일}메틸)아민 및 이의 산 부가염.
  6. (벤질옥시카보닐-이미노-{4'-〔2-(2-프로페녹시)에톡시〕비페닐-4-일}메틸)아민 및 이의 산 부가염.
  7. 〔하이드록시-이미노-(4-{3-〔4-(1-메틸-1-페닐에틸)페녹시메틸〕벤조일옥시}페닐)메틸〕아민 및 이의 산 부가염.
  8. 〔에톡시카보닐-이미노-(4-{3-〔4-(1-메틸-1-페닐에틸)페녹시메틸〕벤조일옥시}페닐)메틸〕아민 및 이의 산 부가염.
  9. 〔3'-피리카보닐-이미노-(4-{3-〔4-(1-메틸-1-페닐에틸)페녹시메틸〕벤질옥시}페닐)메틸〕아민 및 이의 산 부가염.
  10. 제1항 내지 제9항 중 어느 한 항에 따르는 화합물을 약리학적으로 허용되는 희석제, 부형제 및/또는 담체와 함께 포함하는 약제학적 제제.
  11. LBT4- 길항제가 치료적으로 사용될 수 있는 질환 치료용 약제학적 조성물의 제조에 있어서의 제1항 내지 제9항 중의 어느 한 항에 따르는 화합물의 용도.
  12. 감염 및/또는 알러지성 진행이 관련된 질환, 특히 관절염, 천식, 만성 폐색성 폐질환, 건선, 궤양성 대장염, 알쯔하이머병, 쇼크, 아테롬성 동맥경화증, 복합경화증, 비스테로이드성 소염제로 인한 위병, 전이 및 만성 골수병 백혈병의 치료에 있어서의 제1항 내지 제9항 중의 어느 한 항에 따르는 화합물의 용도.
  13. (a) 하기 화학식(Ⅴ)의 아미딘을 하기 화학식(Ⅵ)의 화합물과 반응시키거나, (b) 하기 화학식(Ⅶ)의 화합물을 하기 화학식(Ⅷ) 또는 (Ⅸ)의 벤즈아미딘과 반응시키거나, (c) 하기 화학식(Ⅹ)의 화합물을 하기 화학식(XI) 또는 (XⅡ)의 화합물가 반응시키거나, (d) 하기 화학식(XⅢ)의 니트릴을 하이드록실아민과 반응시켜, R1이 OH인 화학식(Ⅰ)의 화합물을 제조하고, 생성된 생성물로부터 광학 이성체 또는 이성체의 부분입체 이성체쌍 또는 이들의 혼합물을 이들의 특성에 따라 제조할 수 있거나, 염기가 수득되는 경우, 산 부가염을 제조할 수 있고, 산 부가염이 초기에 수득되는 경우, 유리 염기를 수득할 수 있거나, 토오토머 형태를 제조할 수 있고/있거나 분리할 수 있음을 특징으로 하여, 제1항 내지 제9항 중의 어느 한 항에 따르는 화합물을 제조하는 방법.
    상기 화학식(Ⅴ) 내지 (XⅢ)에서, A, R1, R2, R3, R4, R8, R9, X1, X2, X3, X4, m 및 n은 제1항에서 정의한 바와 같고, R'1은 R1과 동일한 의미(단, OH는 제외된다)이며, L은 할로겐 원자(예:Cl 또는 Br) 또는 아실옥시와 같은 친핵 교환성 그룹이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970700124A 1994-07-13 1995-06-03 치환된벤즈아미딘및이의제조방법 KR100421580B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4424713.3 1994-07-13
DE4424713A DE4424713A1 (de) 1994-07-13 1994-07-13 Substituierte Benzamidine, ihre Herstellung und Verwendung als Arnzneistoffe

Publications (2)

Publication Number Publication Date
KR970704675A true KR970704675A (ko) 1997-09-06
KR100421580B1 KR100421580B1 (ko) 2004-07-31

Family

ID=6523047

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700124A KR100421580B1 (ko) 1994-07-13 1995-06-03 치환된벤즈아미딘및이의제조방법

Country Status (37)

Country Link
US (1) US5731332A (ko)
EP (1) EP0770059B1 (ko)
JP (1) JP2931410B2 (ko)
KR (1) KR100421580B1 (ko)
CN (1) CN1083830C (ko)
AT (1) ATE178590T1 (ko)
AU (1) AU700585B2 (ko)
BG (1) BG62090B1 (ko)
BR (1) BR9508374A (ko)
CA (1) CA2194885C (ko)
CO (1) CO4410184A1 (ko)
CZ (1) CZ289376B6 (ko)
DE (2) DE4424713A1 (ko)
DK (1) DK0770059T3 (ko)
EE (1) EE03311B1 (ko)
ES (1) ES2131830T3 (ko)
FI (1) FI970094A0 (ko)
GR (1) GR3030043T3 (ko)
HK (1) HK1011966A1 (ko)
HR (1) HRP950365B1 (ko)
HU (1) HU224823B1 (ko)
IL (1) IL114571A (ko)
MX (1) MX9700273A (ko)
MY (1) MY117090A (ko)
NO (1) NO307373B1 (ko)
NZ (1) NZ287883A (ko)
PE (1) PE32496A1 (ko)
PL (1) PL179595B1 (ko)
RO (1) RO118653B1 (ko)
RU (1) RU2159228C2 (ko)
SA (1) SA95160355B1 (ko)
SK (1) SK281744B6 (ko)
TW (1) TW555738B (ko)
UA (1) UA45351C2 (ko)
WO (1) WO1996002497A1 (ko)
YU (1) YU48934B (ko)
ZA (1) ZA955780B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486181B1 (en) 1992-08-28 2002-11-26 City Of Hope Human leukocutye 12-lipoxygenase and its role in the pathogenesis of disease states
US6191169B1 (en) 1992-08-28 2001-02-20 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
WO1996028427A1 (en) * 1995-03-10 1996-09-19 Berlex Laboratories, Inc. Benzamidine derivatives their preparation and their use as anti-coagulants
EP0743064A1 (en) * 1995-05-17 1996-11-20 Eli Lilly And Company Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease
DE19636689A1 (de) 1996-09-10 1998-03-12 Boehringer Ingelheim Kg Neue Benzamidinderivate
DE19718334A1 (de) 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Neue Benzylaminderivate und Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW513402B (en) * 1997-05-30 2002-12-11 Daiichi Seiyaku Co Process for preparing 3-(7-amidino-2-naphthyl)-2-phenylpropionic acid derivatives
AU1081399A (en) * 1997-10-15 1999-05-03 City Of Hope 12(s)-hete receptor blockers
ID24720A (id) 1997-12-12 2000-08-03 Novartis Ag Senyawa amidino tersubstitusi dalam perawatan penyakit gangguan paru-paru kronis
DE19834713A1 (de) * 1998-07-31 2000-02-03 Boehringer Ingelheim Pharma Neue Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6291531B1 (en) * 1999-10-07 2001-09-18 Boehringer Ingelheim Pharma Kg LTB4 antagonist, processes for the preparation thereof and its use as a pharmaceutical composition
DE10000907A1 (de) * 2000-01-12 2001-07-19 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aryl-iminomethyl-carbaminsäureestern
US6417382B2 (en) 2000-01-12 2002-07-09 Boehringer Ingelheim Pharma Kg Process for preparing aryl-iminomethyl-carbamino acid esters
US6528491B2 (en) * 2000-10-24 2003-03-04 Boehringer Ingelheim Pharma Kg Pyranoside derivatives
CA2433451A1 (en) * 2001-01-16 2002-07-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes
US20030119901A1 (en) * 2001-07-14 2003-06-26 Boehringer Ingelheim Pharma Kg Pharmaceutical formulation containing an LTB4 antagonist
IL159493A0 (en) * 2001-07-14 2004-06-01 Boehringer Ingeiheim Pharma Gm Pharmaceutical formulation containing an ltb4 antagonist
CN1658852A (zh) * 2001-08-31 2005-08-24 神经化学（国际）有限公司 用于治疗淀粉样变性的脒衍生物
RS20050390A (en) * 2002-11-26 2008-04-04 Boehringer Ingelheim Pharma Gmbh. & Co.Kg., Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox 1/2 inhibitor
DE10350528A1 (de) * 2003-10-29 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arzneimittelformulierung, enthaltend einen LTB4-Antagonisten, sowie Verfahren zu deren Herstellung und deren Verwendung
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
CN103012200B (zh) * 2011-09-20 2014-12-17 北京大学 具有β-分泌酶抑制功能的化合物及其制备方法与应用
CN110869362A (zh) 2017-05-12 2020-03-06 国立研究开发法人理化学研究所 A类gpcr结合性化合物改性体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518818A3 (en) * 1991-06-11 1993-04-28 Ciba-Geigy Ag Arylethers, their manufacture and use as medicament
ES2075672T3 (es) * 1991-06-11 1995-10-01 Ciba Geigy Ag Amidinocompuestos, su fabricacion y uso como medicamento.
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
SK281016B6 (sk) * 1992-02-05 2000-10-09 Boehringer Ingelheim Kg Amidínové deriváty, spôsob ich výroby, použitie a farmaceutické prostriedky s ich obsahom
US5455274A (en) * 1992-12-09 1995-10-03 Ciba-Geigy Corporation Hydroxyamidine derivatives

Also Published As

Publication number Publication date
DE4424713A1 (de) 1996-01-18
SK281744B6 (sk) 2001-07-10
AU700585B2 (en) 1999-01-07
US5731332A (en) 1998-03-24
PL318115A1 (en) 1997-05-12
KR100421580B1 (ko) 2004-07-31
CN1083830C (zh) 2002-05-01
ATE178590T1 (de) 1999-04-15
CA2194885A1 (en) 1996-02-01
UA45351C2 (uk) 2002-04-15
NO970122L (no) 1997-01-10
DK0770059T3 (da) 1999-10-18
PE32496A1 (es) 1996-08-12
WO1996002497A1 (de) 1996-02-01
EP0770059A1 (de) 1997-05-02
BG62090B1 (bg) 1999-02-26
NZ287883A (en) 1999-02-25
CZ6697A3 (cs) 1998-02-18
IL114571A (en) 2003-09-17
CA2194885C (en) 2006-04-25
RO118653B1 (ro) 2003-08-29
NO307373B1 (no) 2000-03-27
CZ289376B6 (cs) 2002-01-16
TW555738B (en) 2003-10-01
AU2674295A (en) 1996-02-16
IL114571A0 (en) 1995-11-27
CO4410184A1 (es) 1997-01-09
NO970122D0 (no) 1997-01-10
FI970094A (fi) 1997-01-10
GR3030043T3 (en) 1999-07-30
SA95160355B1 (ar) 2005-06-13
HK1011966A1 (en) 1999-07-23
BG101105A (en) 1998-04-30
SK1997A3 (en) 1997-08-06
ES2131830T3 (es) 1999-08-01
RU2159228C2 (ru) 2000-11-20
YU45295A (sh) 1997-12-05
PL179595B1 (pl) 2000-09-29
YU48934B (sh) 2002-12-10
JP2931410B2 (ja) 1999-08-09
JPH10502645A (ja) 1998-03-10
MY117090A (en) 2004-05-31
CN1152304A (zh) 1997-06-18
DE59505600D1 (de) 1999-05-12
HRP950365A2 (en) 1997-08-31
FI970094A0 (fi) 1997-01-10
HU9700059D0 (en) 1997-02-28
HUT77220A (hu) 1998-03-02
HU224823B1 (en) 2006-02-28
BR9508374A (pt) 1998-05-26
EE03311B1 (et) 2000-12-15
MX9700273A (es) 1997-05-31
HRP950365B1 (en) 2000-04-30
EP0770059B1 (de) 1999-04-07
ZA955780B (en) 1996-01-15

Similar Documents

Publication Publication Date Title
KR970704675A (ko) 치환된 벤즈아미딘, 이의 제조방법 및 약제로서의 이의 용도(Substituted benzamidines, their production and their use as medicaments)
CA2418868A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
RS20060146A (en) Malonamide derivatives blocking the activity of gama-secretase
NO177095C (no) Analogifremgangsmåte for fremstilling av terapeutisk virksomme 2-(l-piperazinyl)-4-fenylcycloalkanopyridin-derivater
JP3103845B2 (ja) １，２，４−オキサジアゾリルフェノキシアルキルイソオキサゾール類及び抗ウイルス薬としてのそれらの用途
CA2509413A1 (en) Benzazepine derivatives for the treatment of neurological disorders
ATE11535T1 (de) N-heteroaryl-alkylendiamine, verfahren zu ihrer herstellung sowie ihre verwendung.
JP2000514083A (ja) 置換ピペラジニル―フェニル―オキサゾリジノン誘導体および抗菌剤としてのその利用
KR970704702A (ko) 치환된 피리미딘 화합물 및 그의 용도(Substituted Pyrimidine Compounds and Their Use)
JP2001526220A5 (ko)
ES2074138T3 (es) Metodo para utilizar (2-imidazolin-2-ilamino)-quinoxalinas para reducir o mantener la presion intraocular.
RU97102043A (ru) Замещенные бензамидины, их получение и применение в качестве лекарственных средств
NZ336628A (en) Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists
KR930019667A (ko) 항-종양 화합물
CA2203274A1 (en) Apolipoprotein-b synthesis inhibitors
WO2002034754A3 (en) Benzoxazinone derivatives, their preparation and use
JO2307B1 (en) Papermidine derivatives
KR900014413A (ko) N-치환된 아미노알칸디포스폰산
KR910006300A (ko) 신규 화합물
DE3064528D1 (en) Substituted-5-((7-chloro-4-quinolinyl)amino)-3-(amino-methyl)-(1,1'-biphenyl)-2-ol compounds; processes for their production; and pharmaceutical compositions containing the compounds
KR910014371A (ko) 인돌일프로판올. 이들의 제조방법. 이들의 용도및 이러한 화합물을 함유하는 제제
RU2004103857A (ru) Производные вариолина и их применение в качестве противоопухолевых средств
JPS5746984A (en) Theobromine derivative and its preparation
ES8200687A1 (es) Un procedimiento para la preparacion de nuevos compuestos amidicos de penicilina
GR3033175T3 (en) Trifluoromethylsulfonylphenyl or trifluoromethylsulfinylphenyl group containing 2-cyano-3-hydroxy-propenamide derivatives, process for their preparation, their use as medicaments and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090130

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee